top of page
Search

CD Markers for MRCP Part 1

TL;DR

For MRCP Part 1, remembering the List: CD Markers (CD3, CD4, CD19, CD20) is essential because these markers repeatedly appear in questions on immunology, haematology, lymphoma and targeted therapies. Rather than memorising isolated numbers, understanding which immune cells express each marker and their clinical significance makes exam questions much easier to solve.


Why this matters

CD markers are routinely used to:

  • Diagnose haematological malignancies

  • Classify lymphomas

  • Identify immune cell populations

  • Monitor HIV infection

  • Guide monoclonal antibody treatment

  • Interpret flow cytometry reports

In MRCP examinations, stems often provide immunophenotyping results rather than naming the disease directly. Recognising a pattern of CD markers frequently leads straight to the diagnosis.


Understanding CD markers

CD stands for Cluster of Differentiation.

These are cell surface molecules recognised by monoclonal antibodies. Different immune cells express characteristic combinations of CD markers, allowing laboratory identification by flow cytometry.

Think of CD markers as molecular identity cards for immune cells.


The five most tested subtopics

1. T-cell markers

The classic T-cell marker is:

  • CD3

All mature T lymphocytes express CD3.

Major subsets include:

  • CD4 → Helper T cells

  • CD8 → Cytotoxic T cells

Clinical relevance:

  • HIV primarily infects CD4 cells.

  • T-cell lymphomas are usually CD3 positive.

  • Flow cytometry commonly reports CD3 positivity when diagnosing T-cell disorders.

2. B-cell markers

The highest-yield B-cell markers include:

  • CD19

  • CD20

  • CD21

  • CD22

  • CD79a

Among these, MRCP repeatedly tests CD19 and CD20.

CD19

  • Earliest reliable B-cell marker

  • Present from early B-cell development

  • Lost after plasma cell differentiation

CD20

  • Mature B-cell marker

  • Not present on plasma cells

  • Target of rituximab

This distinction is extremely important.

3. Natural killer (NK) cell markers

Typical NK-cell phenotype:

  • CD16

  • CD56

Unlike T cells:

  • CD3 negative

Classic exam clue:

CD16+, CD56+, CD3−

This pattern identifies NK cells.

4. Stem cell markers

Important markers include:

  • CD34

  • CD117

CD34 identifies:

  • Haematopoietic stem cells

  • Blast cells in acute leukaemia

Questions on acute leukaemia frequently include CD34 positivity.

5. Therapeutic monoclonal antibodies

Understanding therapeutic targets converts immunology into easy clinical marks.

Examples include:

CD Marker

Cell Type

Clinical Importance

CD3

T cells

T-cell identification

CD4

Helper T cells

HIV monitoring

CD8

Cytotoxic T cells

Cellular immunity

CD19

B cells

CAR-T therapy target

CD20

Mature B cells

Rituximab target

CD34

Stem cells

Acute leukaemia

CD16

NK cells

NK-cell marker

CD56

NK cells

NK-cell marker

CD117

Stem cells

AML marker

CD138

Plasma cells

Multiple myeloma


High-yield points to remember

  1. CD3 identifies all mature T lymphocytes.

  2. CD4 cells are depleted in HIV infection.

  3. CD8 cells kill virus-infected cells.

  4. CD19 appears early during B-cell development.

  5. CD20 disappears once B cells become plasma cells.

  6. Plasma cells are CD138 positive.

  7. NK cells are CD16+, CD56+, CD3−.

  8. CD34 identifies stem cells and blasts.

  9. Rituximab targets CD20.

  10. CAR-T therapies commonly target CD19.

These ten facts account for the majority of CD-marker questions seen in MRCP-style examinations.


Memory tricks

CD3 = Three-letter word "T"

Think:

CD3 → T cells

CD4 = HIV

Whenever HIV appears in the stem, think:

CD4 count

CD19 and CD20

Both are B-cell markers.

Remember:

"Teenagers and twenty-year-olds go to Bar."

19 → B

20 → B

CD20 = Rituximab

Almost every question mentioning rituximab expects recognition of CD20.

CD34

34 resembles a young developing cell.

Think:

Stem cell marker.


Practical example (Mini-MCQ)

A 63-year-old man presents with painless cervical lymphadenopathy. Lymph node biopsy demonstrates a mature B-cell lymphoma. Flow cytometry shows strong expression of CD20.

Which treatment specifically targets this surface antigen?

A. Infliximab

B. Rituximab

C. Trastuzumab

D. Cetuximab

E. Omalizumab

Answer: B. Rituximab

Explanation

Rituximab is a monoclonal antibody directed against CD20 expressed on mature B lymphocytes. It is widely used in:

  • Non-Hodgkin lymphoma

  • Chronic lymphocytic leukaemia

  • Rheumatoid arthritis

  • ANCA-associated vasculitis

Because plasma cells lack CD20, antibody-producing plasma cells are relatively spared.


Practical study-tip checklist

When revising CD markers, always ask yourself:

✔ Is this a T-cell marker?

✔ Is this a B-cell marker?

✔ Is it present on plasma cells?

✔ Is there a monoclonal antibody targeting it?

✔ Does HIV affect this cell?

✔ Is it used in flow cytometry?

✔ Does it identify stem cells?

✔ Is it associated with lymphoma classification?

Reviewing these questions repeatedly is far more effective than rote memorisation.


Doctor revising immunology concepts for MRCP Part 1 preparation.

Common examination traps

  • Confusing CD19 with CD20.

  • Assuming plasma cells express CD20.

  • Forgetting that NK cells are CD3 negative.

  • Mixing CD4 helper cells with CD8 cytotoxic cells.

  • Believing rituximab targets plasma cells.


Revision strategy

An effective approach is:

  1. Learn immune cell types.

  2. Memorise the common CD markers.

  3. Understand associated diseases.

  4. Learn targeted biological therapies.

  5. Practise flow cytometry questions.

Use the Free MRCP MCQs to reinforce these concepts:

Then consolidate with timed practice using:

If you prefer structured teaching, review the relevant immunology sessions in the MRCP lecture series:


Key take-home messages

  • CD3 identifies mature T cells.

  • CD4 marks helper T cells.

  • CD19 and CD20 identify B cells.

  • CD20 is the target of rituximab.

  • NK cells express CD16 and CD56 but not CD3.

  • CD34 is the classic stem-cell marker.

  • Plasma cells lose CD20 and become CD138 positive.

  • Flow cytometry patterns are commonly tested in MRCP Part 1.


FAQs

Which CD marker is most commonly associated with T cells?

CD3 is considered the pan-T-cell marker because it is expressed on virtually all mature T lymphocytes. Questions involving T-cell lymphomas or flow cytometry often rely on recognising CD3 positivity.

Why is CD20 clinically important?

CD20 is expressed on mature B cells and is the therapeutic target of rituximab. Many MRCP questions link CD20 with lymphoma treatment and autoimmune diseases.

Does HIV affect CD19 or CD4 cells?

HIV primarily infects and destroys CD4 helper T lymphocytes, making CD4 count an important marker of disease progression. CD19 is a B-cell marker and is not the primary target of HIV.

Which CD marker identifies stem cells?

CD34 is the classic haematopoietic stem-cell marker and is frequently expressed on blast cells in acute leukaemia. It is commonly reported in flow cytometry and bone marrow immunophenotyping.

How should I revise CD markers for MRCP Part 1?

Focus on recognising immune cell type, associated diseases, therapeutic monoclonal antibodies and common flow cytometry patterns rather than memorising long lists of CD numbers.


Ready to start

Mastering CD markers is one of the easiest ways to gain marks in immunology and haematology. Continue your revision with the MRCP Part 1 overview, reinforce concepts using the Free MRCP QBank, and assess your readiness with full-length mock examinations from Crack Medicine.


Sources

  1. MRCP(UK). https://www.mrcpuk.org/

  2. Abbas AK, Lichtman AH, Pillai S. Basic Immunology. Elsevier.

  3. Hoffbrand AV, Moss PAH. Essential Haematology. Wiley-Blackwell.

  4. WHO Classification of Haematolymphoid Tumours. https://tumourclassification.iarc.who.int/

  5. British Society for Haematology. https://b-s-h.org.uk/

 
 
 

Comments

bottom of page